Navigation Links
Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
Date:11/2/2011

FARMINGDALE, N.Y., Nov. 2, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, announced its recent exhibition of the BoneScalpel™ Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic Surgical Aspiration System at the European Association of Neurosurgical Societies ("EANS"), which was held in Rome, Italy from October 9-14, 2011.  The meeting provided Company representatives the opportunity to demonstrate both systems to a significant percentage of the approximately 1,900 delegates present.

EANS' stated goals are to promote enhanced scientific knowledge and the exchange of information between those in different cultures and training systems throughout Europe.

The SonaStar is used by Neurosurgeons and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

Neurosurgeons, Orthopedic Surgeons and Maxillo-facial/Reconstructive Surgeons use BoneScalpel as a tissue specific osteotomy device to make precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  The device offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.

"We were excited to be part of this meeting of European experts in neurosurgery and spine surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "It exemplifies our commitment to providing products that can contribute to better patient outcomes and to supporting organizations that promote best practices in medicine."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Announces New Distribution Agreement for Mexico
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
10. Misonix Announces New Distribution Agreement for Argentina
11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... 27, 2016  Bayer Animal Health today announced ... the University of Florida College of Veterinary Medicine, ... in Communication Award (BECA). Brittany was selected from ... a total of $70,000 in scholarship funds through ... Bayer has provided a total of $232,500 in ...
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
Breaking Medicine Technology:
(Date:4/29/2016)... San Francisco, CA (PRWEB) , ... April 29, ... ... recently released fertility clinic data for 2014. Each year, reproductive endocrinologists are required ... CDC and SART, the main organization of professionals dedicated to the practice of ...
(Date:4/29/2016)... Los Angeles, California (PRWEB) , ... April 29, 2016 , ... ... all across USA, 1Heart Caregiver Services continues its successful franchise development and expansion as ... Ferdie has an extensive managerial and administrative experience in his 32 years of working ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... announced it has signed a letter of intent with Moda to ... Insurance Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively ...
(Date:4/28/2016)... ... April 28, 2016 , ... CastCoverz!, America’s ... with AquaShieldUSA, the country's oldest waterproof cast protector . As the largest ... the largest selection of daily, night, weatherproof and waterproof covers for most orthopedic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... was among the organization’s most successful events, attracting medical professionals from around the ... and stimulating networking events. , Opening Ceremonies Sunday, April 17 included the introduction ...
Breaking Medicine News(10 mins):